CryoLife, Inc. Announces Release Date And Teleconference Call Details For The Third Quarter 2005 Financial Results

ATLANTA, Oct. 19 /PRNewswire-FirstCall/ -- CryoLife, Inc. , a biomaterials and biosurgical device company, announced today that third quarter 2005 financial results will be released on Thursday, November 3, 2005. The Company will hold a teleconference call and live webcast at 11:15 a.m. Eastern Time, November 3, 2005, to discuss third quarter 2005 financial results followed by a question and answer session hosted by Steven G. Anderson, President and CEO of CryoLife, Inc.

To listen to the live teleconference please dial 973-935-2981 a few minutes prior to 11:15 a.m. A replay of the teleconference will be available November 3 through November 8 and can be accessed by calling (toll free) 877-519-4471 or 973-341-3080. The identification number for the live teleconference and the replay is 6598625.

The live webcast can be accessed by going to the Investor Relations section of the CryoLife web site at http://www.cryolife.com.

About Cryolife, Inc.

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiovascular, vascular, and orthopaedic surgeries throughout the United States and Canada. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels and is CE marked in the European Community and approved in Canada for use in soft tissue repair and approved in Australia for use in vascular and pulmonary sealing and repair. The Company also distributes the CryoLife- O'Brien(R) stentless porcine heart valve and the SG Model #100 vascular graft, which are CE marked for distribution within the European Community.

For additional information about the Company, visit CryoLife's Web site: http://www.cryolife.com

Contact: D. Ashley Lee

EVP, COO & CFO (770) 419-3355

CryoLife, Inc.

CONTACT: D. Ashley Lee, EVP, COO & CFO of CryoLife, Inc., +1-770-419-3355

Back to news